STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #168 by analyst upside · 2026-09-05
TENX
Tenax Therapeutics, Inc.
Healthcare · Market Cap $73M · P/E 0x
ANALYST PRICE TARGET
+547.2%
implied upside to consensus target
Current Price $1.94
Consensus Target $12.56
Bull Target $36.0
Bear Target $4.0
Analysts Covering 9
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
4
Hold
4
Sell
0
52-Week Low $1.31
52-Week High $19.4
YTD Return -82.4%
FUNDAMENTALS
Market Cap $73M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.61
PEG Ratio 1.44
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.31
52-Week High $19.4
Current Price $1.94
Bear Target $4.0
Bull Target $36.0
● Now $1.94 ● Target $12.56
TRADING DATA
Avg Volume 4.9M
YTD Return -82.4%
Analyst Count 9
Consensus Buy
Upside to Target +547.2%
Last Updated 2026-09-05

ANALYST SUMMARY

Tenax Therapeutics, Inc. (TENX) is currently trading at $1.94 with a Wall Street consensus price target of $12.56, implying potential upside of 547.2% over the next 12 months. 9 analysts currently cover TENX, with a consensus rating of Buy - 56% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $36.0, while the most cautious has a target of $4.0.

TENX operates in the Healthcare sector with a market capitalisation of $73M. The stock is down 82.4% year-to-date and is currently trading near the lower end of its 52-week range of $1.31 – $19.4.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TENX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Chardan Capital ↓ Downgrade
Buy → Neutral 2026-08-11 33% win rate (6 calls)
Canaccord Genuity - Reiterated
Buy → Buy 2026-08-11 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-08-11 62% win rate (8 calls)
Evercore ISI Group ↓ Downgrade
Outperform → In-Line 2026-08-11 Building track record
William Blair ↓ Downgrade
Outperform → Market Perform 2026-08-10 44% win rate (9 calls)
Chardan Capital - Reiterated
Buy → Buy 2026-07-31 33% win rate (6 calls)
Cantor Fitzgerald reit
Overweight → Overweight 2026-07-29 40% win rate (10 calls)
Canaccord Genuity ● Initiated
Buy 2026-07-28 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
25
out of 100
Coverage depth
18/30
Consensus clarity
0/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →